Get the Weekly Intelligence Brief — top committee picks every Sunday.
A · NYSE · STOCK

Agilent Technologies (A) Stock Analysis

Healthcare Updated October 10, 2026
$170.59
52W $108.35 – $177.05
53/100
$48.17B
33.5
1.21
AI Committee Verdict
Watch
53/100
Conviction: Contested · 50% agreement · 6 analysts
+5.2%
-13.4%
0.39:1
Contested

Is A Bullish or Bearish?

Mixed. Innellis AI committee rates Agilent Technologies (A) Watch with a composite score of 53/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.42 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.58 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 20.5% shows genuine earnings power backing the valuation — Value
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 33.3 is moderate-to-rich — Value
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 20.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 83%
of 192 Healthcare peers
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 20.5% shows genuine earnings power backing the valuation
− P/E of 33.3 is moderate-to-rich
Growth Analyst bearish
40 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 20.3% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
60 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.5 to 52.6.

Analyst-level changes:
  • Risk Analyst: +1 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
60.2
Neutral
MACD Histogram
-0.472
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$147.78
Resistance
$179.53
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$169.14 Above
EMA 21
$165.19 Above
EMA 50
$156.53 Above
EMA 200
$139.26 Above

Fundamental Analysis

Valuation
37
Growth
69
Profitability
95
Financial Health
99
Cash Flow
70
Valuation
P/E Ratio 33.5×
P/B Ratio 6.53×
PEG Ratio 1.77
Dividend Yield 0.60%
52W High $177.05
52W Low $108.35
Quality & Growth
ROE 1933.0%
ROA 1023.8%
Gross Margin 5373.0%
Operating Margin 2223.3%
Revenue Growth YoY —
Debt / Equity 0.54
AI Fundamental Assessment
P/E ratio of 33.5 (rich relative to a 15-40x range); Price-to-book of 6.5x; PEG ratio of 1.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 19.3%; Return on assets of 10.2%; Net margin of 19.5%; Gross margin of 53.7%; Current ratio of 2.05 (healthy short-term liquidity); Debt-to-equity of 0.54; Free cash flow per share is positive (5.09); Most recent quarter beat estimates by 6.9%; 2 consecutive earnings beats; EPS growth roughly steady (+9.6% -> +8.7% QoQ); Average YoY EPS growth of 18.2%; Analyst estimates rising over recent quarters
Get the Full A Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime